The National Bone Health Alliance working group expanded criteria for the clinical diagnosis of osteoporosis to include T-score < 2.5 at the spine or hip; low-trauma hip fracture; low-trauma vertebral, proximal humerus, pelvis or some distal forearm fractures in the setting of osteopenia; or FRAX score in a patient with osteopenia meeting or exceeding the National Osteoporosis Foundation Guidelines.
The National Bone Health Alliance working group expanded criteria for the clinical diagnosis of osteoporosis to include T-score < 2.5 at the spine or hip; low-trauma hip fracture; low-trauma vertebral, proximal humerus, pelvis or some distal forearm fractures in the setting of osteopenia; or FRAX score in a patient with osteopenia meeting or exceeding the National Osteoporosis Foundation (NOF) Guidelines.
Ethel Siris, MD, from Columbia University College of Physicians and Surgeons, discussed the results of an NBHA working group’s effort to expand the criteria by which a diagnosis of osteoporosis could be made in postmenopausal women and men older than 50 years of age at the 2014 American Society of Bone and Mineral Research Conference in Houston, Texas.
Dr Siris started with a working definition of osteoporosis. It is defined as “a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture, where bone strength is the sum of bone quantity and bone quality.”
At this point in time, greatly improved treatments are available for osteoporosis. However, patients are not seeing the results of this progress. Physicians do not understand how to appropriately use diagnostic tools and do not appropriately diagnose patients. Patients are also reluctant to agree to treatment because they are nervous about side-effects from current drugs.
Currently, the operational criterion for making a diagnosis of osteoporosis in the US focuses on bone mineral density (BMD), particularly T-score threshold at the lumbar spine or hip. Unfortunately, most fractures in postmenopausal women occur in those who carry a diagnosis of osteopenia, leading to disconnect between who is at risk and who gets treated.
As a result of basing diagnosis on BMD, patients may not understand their fracture risk when they are diagnosed with osteopenia, clinicians don’t appropriately treat older post-fracture patients, and third party payers bill differently for payment.
The NBHA addressed these problems by expanding the criteria for osteoporosis:
The diagnosis of osteoporosis should be made in postmenopausal women and men age 50 or older if any one of the following is present:
- T-score < 2.5 at the spine or hip
- Low trauma hip fracture, with or without BMD
- Low trauma vertebral, proximal humerus, pelvis or some distal forearm fractures in the setting of osteopenia
- FRAX score in a patient with osteopenia meeting or exceeding the NOF Guide treatment cut points.
These recommendations are from a US-based committee and depend on how osteoporosis is diagnosed in the United States.
Future directions include gaining endorsements from physician and advocacy groups to change the diagnostic criteria, and having these criteria included in the ICD-9 and ICD-10 diagnostic codes for osteoporosis.
When asked how much these expanded criteria will increase the pool of patients diagnosed with osteoporosis, Dr Siris responded, “Not much.” She noted that the goal of this paper is not necessarily to greatly expand the number of patients receiving treatment; rather, healthcare providers should thoughtfully base their diagnosis of osteoporosis on clinical symptoms (particularly fractures), in addition to the numerical threshold provided by diagnostic tests.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More